Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Inflammation-induced thrombosis: mechanisms, disease associations and management.

Aksu K, Donmez A, Keser G.

Curr Pharm Des. 2012;18(11):1478-93. Review.

PMID:
22364132
2.

[Rheumatoid arthritis, inflammation, and atherosclerosis].

Hürlimann D, Enseleit F, Ruschitzka F.

Herz. 2004 Dec;29(8):760-8. Review. German.

PMID:
15599672
3.

Survival of heparins, oral anticoagulants, and aspirin after the year 2010.

Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.

Semin Thromb Hemost. 2008 Feb;34(1):58-73. doi: 10.1055/s-2008-1066025. Review.

PMID:
18393143
4.

Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis.

Esmon CT.

Baillieres Best Pract Res Clin Haematol. 1999 Sep;12(3):343-59. Review.

PMID:
10856974
5.

Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?

Fareed J, Iqbal O, Cunanan J, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.

Int Angiol. 2008 Jun;27(3):176-92. Review.

PMID:
18506123
6.

Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor.

Tobu M, Iqbal O, Fareed D, Chatha M, Hoppensteadt D, Bansal V, Fareed J.

Clin Appl Thromb Hemost. 2004 Jul;10(3):225-32.

PMID:
15247979
7.

The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients.

Levi M, van der Poll T.

Semin Thromb Hemost. 2008 Jul;34(5):459-68. doi: 10.1055/s-0028-1092876. Epub 2008 Oct 27. Review.

PMID:
18956286
8.

Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients.

Muhlestein JB.

Thromb Haemost. 2010 Jan;103(1):71-82. doi: 10.1160/TH09-03-0177. Epub 2009 Nov 13. Review.

PMID:
20062914
9.

The relevance of blood cell-vessel wall adhesive interactions for vascular thrombotic disease.

May AE, Neumann FJ, Preissner KT.

Thromb Haemost. 1999 Aug;82(2):962-70. Review.

PMID:
10605810
10.

Therapeutic roles of heparin anticoagulants in cancer and related disorders.

Ahmad S, Ansari AA.

Med Chem. 2011 Sep;7(5):504-17. Review.

PMID:
21801147
11.

The interactions between inflammation and coagulation.

Esmon CT.

Br J Haematol. 2005 Nov;131(4):417-30. Review.

PMID:
16281932
12.

Thrombosis in systemic lupus erythematosus: risk and protection.

Burgos PI, Alarcón GS.

Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1541-9. doi: 10.1586/erc.09.137. Review.

PMID:
19954316
13.

Hemostatic changes in vasculitides.

Trifiletti A, Scamardi R, Bagnato GF, Gaudio A.

Thromb Res. 2009 Jul;124(3):252-5. doi: 10.1016/j.thromres.2009.05.019. Epub 2009 Jun 13. Review.

PMID:
19525001
14.

Role of current and emerging antithrombotics in thrombosis and cancer.

Mousa SA.

Drugs Today (Barc). 2006 May;42(5):331-50. Review.

PMID:
16801996
15.
16.

Management of thrombotic and cardiovascular disorders in the new millenium.

Fareed J, Hoppensteadt DA, Bick RL.

Clin Appl Thromb Hemost. 2003 Apr;9(2):101-8. Review.

PMID:
12812377
17.

The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis.

Poredos P, Jezovnik MK.

Int Angiol. 2007 Dec;26(4):306-11. Review.

PMID:
18091697
18.

The coagulant response in sepsis and inflammation.

Levi M.

Hamostaseologie. 2010 Jan;30(1):10-2, 14-6. Review.

PMID:
20162247
19.

Novel anticoagulant agents: introduction.

Schulman S.

J Intern Med. 2003 Oct;254(4):308-12.

20.

Platelets in atherosclerosis.

Lievens D, von Hundelshausen P.

Thromb Haemost. 2011 Nov;106(5):827-38. doi: 10.1160/TH11-08-0592. Epub 2011 Oct 20. Review.

PMID:
22012554

Supplemental Content

Support Center